Novartis Claims New Drugs, Pipeline Will Fuel Growth, Not M&A
Novartis sees itself engaging in only modest M&A activity to avoid over-paying for targets - and will rely on newly launched drugs and promising external targets to grow sales.
Novartis sees itself engaging in only modest M&A activity to avoid over-paying for targets - and will rely on newly launched drugs and promising external targets to grow sales.